Clinical trial
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT03025035
Study timeline
Study start (actual)2017-09-10Date precision: day
Registry last updated2026-02-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
OlaparibDRUG · verified · RxNorm: olaparib
Sponsors & collaborators
Yuan Yuanlead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03025035 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.